NCIRE - The Veterans Health Research Institute Home  |  Sitemap  |  Intranet  |  UltiPro   Visit our Facebook page  Visit our Twitter page  Visit our LinkedIn page

Give Now
About NCIRE Participate in Research Support Our Mission Careers at NCIRE Contact Us
Veterans Health
Research at NCIRE

NCIRE-The Veterans Health Research Institute is the leading private nonprofit institute devoted to Veterans health research in the United States. Our mission is to advance Veterans health through research.

We support the work of some of the nation's foremost physicians and scientists at the San Francisco Veterans Affairs Medical Center, the premier biomedical research facility in the VA system. All have faculty appointments at the University of California, San Francisco, which has its own proud traditions of research and patient care. We also partner with the U.S. Department of Defense to support health research on behalf of our men and women in the Armed Forces.

Those who have served in uniform have given their best for their country. In return, we believe that they deserve nothing less than the best health care research we can provide.

Contact Us
Give Now
Steven A. Yukl, MD

Staff Physician, Medical Service, SFVAHCS
Associate Professor of Medicine, UCSF

Understanding HIV latency reversal

Dr. Steven Yukl is an Associate Professor of Medicine at the University of California, San Francisco (UCSF) and a staff physician at the San Francisco Veterans Affairs Medical Center.  His research focuses on the mechanisms that allow HIV to persist despite immune defenses and current antiviral therapies, thereby preventing HIV cure.  In addition to the immune dysfunction induced by HIV, these barriers to HIV cure include the ability of HIV to establish a reversibly-silent, hidden infection ("latent infection") in some CD4+ T cells in the blood, the persistence of larger numbers of infected cells in the tissues, and the possibility that HIV medicines do not stop all viral replication.  The goals of current research are: 1)  to determine the cell types and tissues in which HIV persists during antiviral therapy; 2) to determine the mechanisms that govern latent HIV infection in the blood and tissues; 3) to measure the degree to which different therapies reverse HIV latency and lead to death of HIV-infected cells in vivo;  and 4) to identify the best model for testing new therapies and combinations designed to disrupt latent HIV infection.


To view Dr. Yukl on Pub Med, click here.